I know some people will read this and think I am just being negative, because they believe that if selling unstudied, unregulated products keeps MIDI afloat, then its a win
NAC in very high doses (above 1800mg daily) can theoretically affect cysteine metabolism and insulin signalling, which may be relevant for diabetic patients on tirzepatide, but this is uncommon at standard supplementation levels
Therefore, additional studies are required to assess the impact of cardiovascular, renal and hepatic outcomes, which could be compared in a future NMA
MK-677 (ibutamoren) is not a peptide at all but a small-molecule, orally active GHS-R1a agonist the practical advantage being that it survives the gut and can be taken by mouth, with a longer duration of action than the injectable peptides
Balette sees microdosing less as a trend and more as a way for patients and clinicians to avoid big swings when full-dose treatment is hard to tolerate or sustain